申请人:GENENTECH, INC.
公开号:EP0623343A1
公开(公告)日:1994-11-09
5,6-Dehydronorketamine and derivatives retaining the α,β-unsaturated carbonyl are disclosed. These and other Michael or Michael-type acceptors and adducts are shown to influence the replication, differentiation or maturation of blood cells, especially platelet progenitor cells. Accordingly, these compounds are used for treatment of thrombocytopenia.
本文公开了保留α,β-不饱和羰基的5,6-去氢诺可胺及其衍生物。这些化合物以及其他麦克尔或麦克尔型受体和加合物被证明能够影响血细胞的复制、分化或成熟,特别是血小板祖细胞。因此,这些化合物被用于治疗血小板减少症。